Touching a network across healthcare in pharma, payer and provider, MMIT's team of experts takes a closer look at Multiple Sclerosis treatments in our most recent Reality Check. The following highlights some of our key takeaways from the piece, which can be viewed below.
Payer Coverage: Utilization management from top payers reveals the limited amount of step edits and prevalence of PA policies. Over half of the largest players require prior authorizations for leading drugs.
Source: MMIT data as of Q4 2015
Trends: Recent Multiple Sclerosis news reveals some key trends within the market basket. Pharmaceutical manufacturers and providers team up to develop innovative treatments for patients suffering from the disease. A piece from WNYT highlights one MS treatment currently undergoing clinical trials for relapsing remitting and primary progressive MS. However, M&As and corporate restructure dominate the pharma landscape, raising concern for the future of the MS class. An article from Fierce Biotech describes Biogen's recent drop of their Phase II MS drug, Tecfidera, to divert efforts to Alzheimer's R&D.
Key Findings: MMIT's pharmacists reveal several key findings when taking a closer look at the data for Multiple Sclerosis. Several treatments in the near-term pipeline will emerge over the coming years, which will affect MS market access. The generic version of Copaxone will provide strong incentives for pharmacies and payers to adopt the new treatment. Using effective payer contracting strategies, brand teams have opportunities to replace existing Copaxone payer relationships. Finally, the limited use of medical benefit in Multiple Sclerosis is evident. With the exception of Tysabri and Lemtrada, most brands process exclusively through pharmacy benefit.
In the full Reality Check on Multiple Sclerosis below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within MS.